 |
 |
|
|
|
RESÚMENES FEBRERO 2010 |
Schizophrenia-Psychotic
Disorders & Antipsychotics
(Haga un click en la
información del journal
para acceder al resúmen)
5
– doble-ciego o
metanálisis; 4 – subanálisis o simple ciego; 3
– revisión, abierto, básico; 2 –
casos; 1 – opinión
GRATIS = Texto
gratuito en algunos países de la región iberoamericana
3! - Twenty-five
year mortality of a community cohort with schizophrenia
Steve
Brown, Miranda Kim, Clemence Mitchell, Hazel Inskip
The British Journal of Psychiatry (2010) 196: 116-121
4 -
The risk of death among adult participants in trials of antipsychotic drugs in
schizophrenia
Maria
Isaac and Armin Koch
European
Neuropsychopharmacology. Volume 20, Issue 3, March 2010, Pages 139-145
3 -
Effects of repeated risperidone exposure on serotonin receptor subtypes in
developing rats
Yong
Kee Choi, Taylor Moran-Gates, Matthew P. Gardner and Frank I. Tarazi
European
Neuropsychopharmacology. Volume 20, Issue 3, March 2010, Pages 187-194
3! - Nonadherence to Medication Four Years After a First
Episode of Psychosis and Associated Risk Factors
Michele Hill, Niall Crumlish,
Petter Whitty, Mary Clarke, Stephen Browne, Moayyad Kamali, Anthony Kinsella,
John L. Waddington, Conall Larkin, Fand Eadbhard O'Callaghan
Psychiatr Serv 61:189-192,
February 2010
5 - Olanzapine Long-Acting Injection: A 24-Week, Randomized,
Double-Blind Trial of Maintenance Treatment in Patients With Schizophrenia
John M. Kane, Holland C. Detke,
Dieter Naber, Gopalan Sethuraman, Daniel Y. Lin, Richard F. Bergstrom, and
David McDonnell
Am J Psychiatry 2010;
167:181-189
5 - Long-Chain ω-3 Fatty Acids for Indicated Prevention of
Psychotic Disorders. A Randomized, Placebo-Controlled Trial
G. Paul Amminger, Miriam R.
Schäfer, Konstantinos Papageorgiou, Claudia M. Klier, Sue M. Cotton, Susan M.
Harrigan, Andrew Mackinnon, Patrick D. McGorry, Gregor E. Berger
Arch Gen Psychiatry. 2010;67(2):146-154
3 - Polypharmacy in schizophrenia
Zink,
Mathias; Englisch, Susanne; Meyer-Lindenberg, Andreas
Current Opinion in Psychiatry:
March 2010 - Volume 23 - Issue 2 - p 103–111
3 - Why do patients with schizophrenia smoke?
Winterer,
Georg
Current Opinion in Psychiatry:
March 2010 - Volume 23 - Issue 2 - p 112–119
3 - The association between class of antipsychotic and
rates of hospitalization: Results of a retrospective analysis of data from the
2005 medicare current beneficiary survey
Jae Kennedy, Yu Yu Tien,
Lawrence J. Cohen, David Alexander Sclar, Darren Liu, Elizabeth G. Blodgett and
Josh Engle
Clinical Therapeutics. Volume
31, Issue 12, December 2009, Pages 2931-2939
3! -
Prenatal exposure to tobacco and risk for schizophrenia: a retrospective
epidemiological study
Audrey
Baguelin-Pinaud, Sylvie Robert, Jean-François Ménard and Florence Thibaut
Comprehensive
Psychiatry. Volume 51,
Issue 2, March-April 2010, Pages 106-109
3! -
Mortality in Kraepelinian schizophrenic patients: a prospective study with a
median follow-up of 8.4 years
Gwenolé
Loas, Pénélope Descle and Valérie Yon
Comprehensive
Psychiatry. Volume 51,
Issue 2, March-April 2010, Pages 151-156
5 - A randomised controlled
study of risperidone and olanzapine for schizophrenic patients with
neuroleptic-induced acute dystonia or parkinsonism
HY Chan,
CJ Chang, SC Chiang, JJ Chen, CH Chen, HJ Sun, HG Hwu, MS Lai
Journal
of Psychopharmacology, Vol. 24, No. 1, 91-98 (2010)
3 - Does Oral Antipsychotic Pre-Treatment Influence Outcome of a Switch to
Long-Acting Injectable Risperidone in Patients with Schizophrenia?
M. Schmauß, B. Diekamp, M. Gerwe,
A. Schreiner, B. Ibach
Pharmacopsychiatry. February
2009
3 - Risperidone long-acting therapy in stable patients
with recently diagnosed schizophrenia
Macfadden,
Wayne; Bossie, Cynthia A.; Turkoz, Ibrahim; Haskins, John Thomas
International Clinical
Psychopharmacology: March 2010 - Volume 25 - Issue 2 - pp 75-82
GRATIS 3
- Optimizing treatment of schizophrenia to minimize relapse
Ludovic Samalin, Olivier Blanc & Pierre-Michel
Llorca
Expert Review of
Neurotherapeutics. February 2010, Vol. 10, No. 2, Pages 147-150
3 - Clozapine and cardiometabolic health in chronic
schizophrenia: correlations and consequences in a clinical context
Gin Malhi
Australasian Psychiatry. February 2010, Vol. 18, No. 1, Pages 32-41
3 - Heart rate variability in bipolar mania and
schizophrenia
Brook L. Henry, Arpi
Minassian, Martin P. Paulus, Mark A. Geyer and William Perry
Journal of Psychiatric Research. Volume 44, Issue 3, February 2010, Pages 168-176
3! -
Do antipsychotic medications reduce or increase mortality in schizophrenia? A
critical appraisal of the FIN-11 study
Marc
De Hert, Christoph U. Correll and Dan Cohen
Schizophrenia
Research. Volume
117, Issue 1, March 2010, Pages 68-74
3! - Prevalence of cardiovascular risk factors and
disease in people with schizophrenia: A population-based study
Lauren C. Bresee, Sumit
R. Majumdar, Scott B. Patten and Jeffrey A. Johnson
Schizophrenia Research. Volume
117, Issue 1, March 2010, Pages 75-82
3 - GABA concentration in schizophrenia patients and
the effects of antipsychotic medication: A proton magnetic resonance
spectroscopy study
Shin'Ya Tayoshi, Masahito
Nakataki, Satsuki Sumitani, Kyoko Taniguchi, Sumiko Shibuya-Tayoshi, Shusuke
Numata, Jun-ichi Iga, Shu-ichi Ueno, Masafumi Harada and Tetsuro Ohmori
Schizophrenia Research. Volume
117, Issue 1, March 2010, Pages 83-91
3! - Central nervous system
effects of haloperidol on THC in healthy male volunteers
Marieke
Liem-Moolenaar, Erik T. Te Beek, Marieke L. de Kam, Kari L. Franson, René S. Kahn,
Ron Hijman, Daan Touw, and Joop M.A. van Gerven
Journal
of Psychopharmacology. First published on February 8, 2010
3 - Dual Diagnosis Psychosis and Substance Use Disorders in Adolescents -
Part 1
K. Meister, M. Burlon, L. Rietschel,
E. Gouzoulis-Mayfrank, T. Bock, M. Lambert
Fortschr Neurol Psychiatr
2010; 78(2): 81-89
3 - Treatment with Olanzapine is Associated with
Modulation of the Default Mode Network in Patients with Schizophrenia
Fabio Sambataro,
Giuseppe Blasi, Leonardo Fazio, Grazia Caforio,
Paolo Taurisano, Raffaella Romano, Annabella Di Giorgio,
Barbara Gelao, Luciana Lo Bianco, Apostolos Papazacharias,
Teresa Popolizio, Marcello Nardini and Alessandro Bertolino
Neuropsychopharmacology (2010)
35, 904–912
3 - A naturalistic controlled
study of relapsing schizophrenic patients with tardive dyskinesia and
supersensitivity psychosis
Paul
Fallon and Serdar M Dursun
Journal
of Psychopharmacology. First published on February 10, 2010
5 - Review and meta-analysis
of usage of ginkgo as an adjunct therapy in chronic schizophrenia
Vidhi Singh, Surendra P.
Singh and Kelvin Chan
The International Journal of
Neuropsychopharmacology (2010), 13:257-271
2! - Case Reports of
Postmarketing Adverse Event Experiences With Olanzapine Intramuscular Treatment
in Patients With Agitation
Stephen
R. Marder, Sebastian Sorsaburu, Eduardo Dunayevich, Jamie L. Karagianis, Ian C.
Dawe, Deborah M. Falk, Mary Anne Dellva, Janice L. Carlson, Patrizia A.
Cavazzoni, and Robert W. Baker
J Clin Psychiatry. February 2009
3! - Incidence of Tardive
Dyskinesia With Atypical Versus Conventional Antipsychotic Medications: A Prospective
Cohort Study
Scott
W. Woods, Hal Morgenstern, John R. Saksa, Barbara C. Walsh, Michelle C.
Sullivan, Roy Money, Keith A. Hawkins, Ralitza V. Gueorguieva, and William M.
Glazer
J Clin Psychiatry, February 2009
3 - Sexual dysfunction in Japanese patients with
schizophrenia treated with antipsychotics
Akira Fujii, Norio
Yasui-Furukori, Norio Sugawara, Yasushi Sato, Taku Nakagami, Manabu Saito and
Sunao Kaneko
3 - Lipid status, anti-oxidant enzyme defence and
haemoglobin content in the blood of long-term clozapine-treated schizophrenic
patients
Cedo Miljevic, Milan
Nikolic, Aleksandra Nikolic-Kokic, David R. Jones, Vesna Niketic, Dusica Lecic-Tosevski
and Mihajlo B. Spasic
3! - QTc prolongation and antipsychotic medications in
a sample of 1017 patients with schizophrenia
Yuji Ozeki, Kumiko Fujii,
Naoki Kurimoto, Naoto Yamada, Masako Okawa, Takesuke Aoki, Jun Takahashi,
Nobuya Ishida, Minoru Horie and Hiroshi Kunugi
3 - Metformin for Atypical Antipsychotic-Induced Weight
Gain and Glucose Metabolism Dysregulation: Review of the Literature and
Clinical Suggestions
Hasnain,
Mehrul; Vieweg, W. Victor R; Fredrickson, Sonja K
CNS Drugs: 1 March 2010 -
Volume 24 - Issue 3 - pp 193-206
3 - Intramuscular Paliperidone Palmitate
Hoy,
Sheridan M; Scott, Lesley J; Keating, Gillian M
CNS Drugs: 1 March 2010 -
Volume 24 - Issue 3 - pp 227-244
3! - Predictors of Early Worsening after Switch to
Aripiprazole: A Randomized, Controlled, Open-Label Study
Pae, Chi-Un; Chiesa, Alberto;
Mandelli, Laura; Patkar, Ashwin A; Gibiino, Sara; Serretti, Alessandro
Clinical Drug Investigation: 1
March 2010 - Volume 30 - Issue 3 - pp 187-193
5 - Modeling the Effectiveness of Paliperidone ER and
Olanzapine in Schizophrenia: Meta-Analysis of 3 Randomized, Controlled Clinical
Trials
Ignacio Ortega, Juan Jose Perez-Ruixo, Kim
Stuyckens, Vladimir Piotrovsky, and An Vermeulen
J Clin Pharmacol 2010 50: 293
-310
3! - Tolvaptan: a new tool for the effective treatment of
hyponatremia in psychotic disorders
Richard C Josiassen, Jessica Curtis, Dawn M Filmyer, Brett Audino, Nina Skuban
& Rita
A Shaughnessy
Expert Opinion on Pharmacotherapy. March 2010, Vol. 11, No. 4, Pages 637-648
3! - Obesity and smoking in patients with schizophrenia
and normal controls: A case-control study
Konstantinos N.
Fountoulakis, Melina Siamouli, Panagiotis Panagiotidis, Stamatia Magiria,
Sotiris Kantartzis, Natalia Papastergiou, George Shoretsanitis, Eleonora
Pantoula, Katerina Moutou, Evangelia Kouidi and Symeon Deres
Psychiatry Research. Volume 176, Issue 1, 30 March 2010, Pages 13-16
3 - Neutropenia Induced by Second Generation Antipsychotics: A Prospective
Investigation
M. A. Rettenbacher, A. Hofer,
G. Kemmler, W. W. Fleischhacker
Pharmacopsychiatry. February
2010
3 - Determination of clozapine
in serum of patients with schizophrenia as a measurement of medication
compliance
S. Mennickent
International Journal of Psychiatry in Clinical
Practice. March
2010, Vol. 14, No. 1, Pages 41-46
3 - Long-term observation of patients successfully
switched to risperidone long-acting injectable: A retrospective, naturalistic
18-month mirror-image study of hospitalization rates and therapy costs
Birgit Spill
International Journal of Psychiatry in Clinical
Practice. March
2010, Vol. 14, No. 1, Pages 53-62
3! - Antipsychotic Polypharmacy
and Risk of Death From Natural Causes in Patients With Schizophrenia: A
Population-Based Nested Case-Control Study
Lone
Baandrup, Christiane Gasse, Vibeke D. Jensen, Birte Y. Glenthoj, Merete
Nordentoft, Henrik Lublin, Anders Fink-Jensen, Anne Lindhardt, and Preben B.
Mortensen
J
Clin Psychiatry 2010;71(2):103-108
5 - A Double-Blind, Randomized
Study of Minocycline for the Treatment of Negative and Cognitive Symptoms in
Early-Phase Schizophrenia
Yechiel
Levkovitz, Shlomo Mendlovich, Sharon Riwkes; Yoram Braw, Hana
Levkovitch-Verbin, Gilad Gal, Shmuel Fennig, Ilan Treves, and Shmuel Kron
J
Clin Psychiatry 2010;71(2):138-149
3 - Positron Emission
Tomography Measurement of Dopamine D2 Receptor Occupancy in the
Pituitary and Cerebral Cortex: Relation to Antipsychotic-Induced
Hyperprolactinemia
Ryosuke
Arakawa, Masaki Okumura, Hiroshi Ito, Akihiro Takano, Hidehiko Takahashi, Harumasa
Takano, Jun Maeda, Yoshiro Okubo, and Tetsuya Suhara
J
Clin Psychiatry, February 2010
3! - Amisulpride versus olanzapine in the treatment of
schizophrenia in Indian patients: randomized controlled trial
Subhrojyoti Bhowmick, Avijit Hazra, Malati Ghosh
Australian and New Zealand Journal of Psychiatry. March 2010, Vol. 44, No.
3, Pages 237-242
| Regresar a RESÚMENES FEBRERO 2010 |
©
1999-2010 Jorge M Tamayo, MD, BMSS
Creada en Enero 1999
| Declaración: El contenido de esta página web está basado en las revisiones de la literatura realizadas por el autor y las colaboraciones enviadas por los lectores. Este sitio de Internet está dirijido únicamente a profesionales de la salud en Iberoamérica. Si usted es residente de Estados Unidos de América o Europa, debe tener en cuenta que los contenidos no han sido escogidos con base en información aprobada por la FDA o la EMEA |